Chitosan Derivatives for Soluble, Low-Toxicity Antimicrobial Synergy
Solution Overview
Problem
Existing chitosan derivatives exhibit low solubility and high toxicity, limiting their effectiveness as antimicrobial agents, and there is a need for synergistic combinations with antibiotics to overcome bacterial resistance.
Innovation Solution
Development of chitosan derivatives with specific structural modifications, such as compounds of formula I, which enhance solubility and biocompatibility, and demonstrate synergistic antimicrobial effects when combined with antibiotics like ampicillin, carbenicillin, meropenem, novobiocin, tobramycin, amikacin, and rifampicin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If chitosan derivatives are modified with hydrophobic moieties to enhance antimicrobial activity, then membrane disruption ability is improved, but biocompatibility deteriorates due to high hemolytic activity and cytotoxicity
Solution Approach 1:
The patent modifies the chemical structure of chitosan by introducing specific amino groups at positions 2 and 6 of the glucosamine unit, changing the molecular parameters to achieve enhanced antimicrobial activity while maintaining biocompatibility. The specific substitution pattern (2,6-diamino) optimizes the balance between membrane disruption capability and cellular toxicity
Solution Approach 2:
The patent creates a composite structure by combining chitosan backbone with specific amino group substitutions, forming a new derivative (2,6-DAC) that integrates the beneficial properties of both components: the cationic nature of chitosan for membrane interaction and the enhanced solubility and reduced toxicity from the amino modifications
2Strength
If chitosan derivatives are modified to enhance antimicrobial efficacy, then antibacterial activity is improved, but solubility deteriorates due to aggregation and reduced water solubility
Solution Approach 1:
The patent changes the chemical parameters of chitosan by introducing hydrophilic amino groups at positions 2 and 6, which increase water solubility and prevent aggregation while maintaining the cationic charge density necessary for antimicrobial activity. This parameter optimization resolves the contradiction between efficacy and solubility
3Object-affected harmful factors
If conventional chitosan is used as antimicrobial agent, then biocompatibility is maintained, but antimicrobial efficacy is insufficient to combat multi-drug resistant bacteria
Solution Approach 1:
The patent applies local quality modification by specifically targeting positions 2 and 6 of the glucosamine unit for amino group substitution, creating localized enhancements in antimicrobial activity while preserving the overall biocompatible nature of the chitosan backbone. This localized modification strategy achieves superior efficacy without sacrificing biocompatibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified chitosan derivatives show broad antimicrobial activity and synergistic effects with antibiotics, enhancing bacterial sensitivity and reducing toxicity, as demonstrated by in vitro and in vivo studies.
Implementation Method 1
the cationic polymer can interrupt cytoplasmic membrane and cause the leakage of cytosol, resulting in the death of bacteria
Implementation Method 2
chitosan backbones tend to aggregate by formation of hydrogen bonds
Implementation Method 3
the aggregated chitosan nanoparticle without hydrophobic moieties functions as a cationic proton sponge, which can be used as an effective antimicrobial agent with high biocompatibility
Data Source
AI summary
Disclosed herein is a compound of formula I:where m, n and R1 are as defined herein. Also disclosed herein are uses of the compound.